This study demonstrated that nivolumab has statistically and clinically significant benefits for patients who have received two or more lines of chemotherapy and have not been selected for PD‐L1 expression.32 In Japan, another study also reported a preliminary result of the safety and activity of nivolumab in patients with esophageal cancer. The gene discussed is CD274; the disease is esophageal cancer.